Prostate Institute of America

At the Prostate Institute of America, we focus on empowering our patients to make decisions for their care and treatment by providing the best possible information regarding their unique case. We emphasize early detection, accurate diagnosis, minimally invasive treatment options with maximum survivability potential, and a multidisciplinary, multi-team approach that gives each patient a complete understanding of their disease and individual treatment plan.

The Prostate Institute is located in the
Community Memorial Hospital Mountain Tower
147 N. Brent Street, Ventura, California
Schedule an Appointment: 805/948-3082

Prostate Services:

  • Prostate Specific Antigen (PSA) testing
  • Digital Rectal Exams (DRE)
  • Color-Doppler Transrectal Ultrasound (TRUS)
  • Biopsy
  • Ultrasound
  • Cryotherapy
  • Focal Cryotherapy
  • Active Surveillance
  • Prostatitis Injections

Meet Our Physicians

Duke Bahn, M.D.
View Profile

Duke Bahn, M.D.

Internationally recognized as one of the leading practitioners in the study and treatment of prostate cancer, Dr. Duke K. Bahn is the director of the Prostate Institute of America at CMH. His special areas of interest are the early detection and staging of prostate cancer using color-Doppler ultrasound with tissue harmonics. He is also a pioneer in using cryotherapy, as both a primary and salvage treatment for prostate cancer. Certified by the American Board of Radiology, Dr. Bahn spent more than 20 years in the research and development of a cryoablation procedure for an effective prostate cancer treatment. His published data was the impetus for obtaining Medicare approval for cryotherapy as a viable primary treatment for prostate cancer. Dr. Bahn actively promotes prostate cancer education and patient empowerment through his extensive speaking appearances throughout the world.

William Klope, M.D.
View Profile

William Klope, M.D.

Dr. William Klope attended Pepperdine University in Malibu, California, and graduated cum laude with a Bachelor of Science in biology. He earned his medical degree from Vanderbilt University School of Medicine in Nashville, Tennessee, and then went on to complete a residency in urologic surgery at the Louisiana State University Medical Center and Charity Hospital in New Orleans. Following his residency, Dr. Klope entered active duty in the United States Navy. He served as staff urologist and an instructor in the Family Practice Residency Program. Dr. Klope is board certified by the American Board of Urology and is on staff at CMH. He is also fluent in Spanish.

Prostate cancer accounts for 36% of all male cancers in the United States and 13% of all cancer related deaths in men.

Dr. Duke Bahn

About Prostate Cancer

Adenocarcinoma of the prostate is the clinical term for cancer that begins in the glandular structure of the prostate. If identified while it is confined within the prostate, the cancer can be treated successfully. The longer prostate cancer is ignored, the greater the chance that it will metastasize (spread), first locally to tissues around the prostate, or seminal vesicles (saclike structures attached to the prostate), then to other parts of the body, such as lymph nodes, bones, liver and lungs.

Early detection and intervention of progressive prostate cancer may help decrease the 30,000 prostate cancer-related deaths each year. Treated in its early stages, prostate cancer is highly survivable.

Prostate Cancer Risk Factors

Men with a family history of prostate cancer are considered to be at high risk. Research suggests that high dietary fat is also a prominent risk factor. There may be a hereditary factor, but no gene has been identified.

Other possible risk factors include the following:

  • Age (96% of cases occur in men over 55)
  • Exposure to heavy metals (e.g., cadmium)
  • Infectious agents
  • Low exposure to ultraviolet light
  • Race (African American men have the highest rate)
  • Smoking
  • Farmers (probably due to pesticide use)
  • Airline pilots
  • Vietnam veteran